Clinical
Implications of Resistance Session Posters
Risk of development of drug resistance
in patients starting antiretroviral therapy with three or more drugs in routine
clinical practice
AN Phillips
Estimation
of phenotypic clinical cutoffs for VirtualPhenotype. through meta analyses of
clinical trial and cohort data
LT Bacheler
Does drug class multi-resistance affect survival? Analysis from a cohort of
HIV patients who experienced treatment failure
M Zaccarelli
Previously
unclassified mutations at positions associated with antiretroviral drug resistance
SY Rhee
Risk of developing selected de
novo resistance mutations during structured therapy interruption (STI) in chronic
HIV-1 infection
M Arnedo
Baseline predictors and virological
outcome in subjects developing mutations during intermittent HAART
L Palmisano
Treatment
interruption in patients with multiple failures to ARV therapy: can the controversy
be solved?
D Costagliola
Determinants of replication capacity
(RC) in HIV-1 isolates from antiretroviral (ART)-experienced adults failing
a PI-based regimen, and relationship of RC with HIV-1 RNA and CD4 counts
R Haubrich
Impact of three or four protease
mutations at codons 33, 82, 84 and 90 on 2 week virological responses to tipranavir,
lopinavir, amprenavir and saquinavir all boosted by ritonavir in Phase 2B trial
BI 1182.51
DL Mayers
Minor protease inhibitor resistant
variants, even at very low level, can drive the failure resistance mutations
profiles of subsequent protease inhibitor-based regimen
V Calvez
Reverse-transcriptase mutation
M184V delays the selection of thymidine-analogue mutations in children infected
with subtype-C
HIV-1
Z Grossman
Genotypic reverse transcriptase evolution in antiretroviral-experienced patients
receiving tenofovir DF-containing regimens
B Masquelier
Clinical and genotypic correlates
of K65R mutation in an unselected cohort of HIV-infected persons naive for tenofovir
A Antinori
Development
of resistance mutations in patients receiving salvage therapy with tenofovir
B Conway
Dynamic
of selection of the K65R and M184V/I mutations in patients enrolled in Tonus
trial
D Descamps
Early
virological failure and occurence of resistance in naive patients receiving
tenofovir, didanosine and efavirenz
D Podzamczer
Impact of HIV resistance mutations,
drug resistance and viral fitness on antiviral activity of tenofovir/abacavir/lamivudine
in the ESS30009 study
LL Ross
Persistance of nevirapine-resistant
virus and pharmacokinetic analysis in women who received intrapartum NVP associated
to a short course of zidovudine (ZDV) to prevent perinatal HIV-1 transmission:
the Ditrame Plus ANRS 1201/02 Study, Abidjan, Côte d'Ivoire
ML Chaix
The V106M mutation in treatment
failures from a randomized controlled trial of lamivudine and stavudine, with
nevirapine and/or efavirenz
DB Hall
Substitutions within HIV gp41
amino acids 36-45 are identified as the primary determinants for loss of in
vitro susceptibility to enfuvirtide: results of data mining analyses of genotypic
changes in gp41 in TORO 1 and TORO 2 that associate with changes in phenotypic
susceptibility to enfuvirtide
C Su
Rate of virological failure and
resistance profiles in patients treated with triple nucleoside regimens
V Soriano
